Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study.
Eerkens AL, Brummel K, Vledder A, Paijens ST, Requesens M, Loiero D, van Rooij N, Plat A, Haan FJ, Klok P, Yigit R, Roelofsen T, de Lange NM, Klomp R, Church D, Ter Elst A, Wardenaar R, Spierings D, Foijer F, Koelzer VH, Bosse T, Bart J, Jalving M, Reyners AKL, de Bruyn M, Nijman HW. Eerkens AL, et al. Nat Commun. 2024 Sep 3;15(1):7695. doi: 10.1038/s41467-024-52098-8. Nat Commun. 2024. PMID: 39227583 Free PMC article. Clinical Trial.
APOLLO: neo-adjuvant pembrolizumab for primary vulvar squamous cell carcinoma-a multicenter, single-arm, phase II, clinical proof-of-concept study.
van Poelgeest MIE, Kortekaas KE, van Doorn HC, Oonk M, Nijman HW, Boere I, Eerkens AL, Reyners AKL, Ewing-Graham PC, Bart J, Bosse T, Welters MJP, Kroep JR, van der Burg SH. van Poelgeest MIE, et al. Among authors: eerkens al. Int J Gynecol Cancer. 2024 Jul 2:ijgc-2024-005523. doi: 10.1136/ijgc-2024-005523. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 38909994